Abstract:Regulation of ubiquitination is associated with multiple processes of tumorigenesis and development, including regulation of the tumor immune microenvironment. Deubiquitinating enzymes (DUBs) can remove ubiquitin chains from substrates, thereby stabilizing target proteins and altering and remodeling biological processes. During tumorigenesis, deubiquitination-altered biological processes are closely related to tumor metabolism, stemness, and the immune microenvironment. Recently, tumor microenvironment (TME) modulation strategies have attracted considerable attention in cancer immunotherapy. Targeting immunosuppressive mechanisms in the TME has revolutionized cancer therapy. Prostate cancer (PC) is one of the most common cancers and the second most common cause of cancer-related death in men worldwide. While immune checkpoint inhibition has produced meaningful therapeutic effects in many cancer types, clinical trials of anti-CTLA4 or anti-PD1 have not shown a clear advantage in PC patients. TME affects PC progression and also enables tumor cell immune evasion by activating the PD-1/PD-L1 axis. Over the past few decades, an increasing number of studies have demonstrated that deubiquitination in PC immune microenvironment may modulate the host immune system’s response to the tumor. As the largest and most diverse group of DUBs, ubiquitin-specific proteases (USPs) play an important role in regulating T cell development and function. According to current studies, USPs exhibit a high expression signature in PC and may promote tumorigenesis. Elevated expression of USPs often indicates poor tumor prognosis, suggesting that USPs are expected to develop as the markers of tumor prognosis and even potential drug targets for anti-tumor therapy. Herein, we first summarized recent advances of USPs in PC and focused on the relationship between USPs and immunity. Additionally, we clarified the resistance mechanisms of USPs to targeted drugs in PC. Finally, we reviewed the major achievement of targeting USPs in cancers.

Roles of Ubiquitination and SUMOylation on Prostate Cancer: Mechanisms and Clinical Implications

Dissecting Multiple Roles of SUMOylation in Prostate Cancer.

Roles of Ubiquitination in the Crosstalk Between Tumors and the Tumor Microenvironment (Review)

Role of ubiquitin specific proteases in the immune microenvironment of prostate cancer: A new direction

The role of protein post-translational modifications in prostate cancer

Potential Novel Targets in Prostate Cancer Treatment

Post-Translational Modification of SUMOylation and Cancer: A Brief Review

The Emerging Roles of SUMOylation in the Tumor Microenvironment and Therapeutic Implications

[Research Progress of the Roles of Ubiquitination/Deubiquitination in Androgen Receptor Abnormalities and Prostate Cancer].

The post-translational modification, SUMOylation, and cancer (Review)

Proteasome dysregulation in human cancer: implications for clinical therapies

Role of Desumoylation in the Development of Prostate Cancer

Impact of Posttranslational Modifications in Pancreatic Carcinogenesis and Treatments

Regulation of Glucose, Fatty Acid and Amino Acid Metabolism by Ubiquitination and SUMOylation for Cancer Progression

Small Ubiquitin-Like Modifier Protein-Specific Protease 1 and Prostate Cancer

Ubiquitin B, Ubiquitin C, and β-Catenin as Promising Diagnostic and Prognostic Tools in Prostate Cancer

Roles of SUMOylation and De-Sumoylation in Carcinogenesis

SUMOylation Homeostasis in Tumorigenesis

Epigenetic regulation of prostate cancer: the theories and the clinical implications

Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications